Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: J Immunol. 2016 Dec 16;198(2):623–628. doi: 10.4049/jimmunol.1601686

Figure 1. A2aR signaling using the selective agonist CGS-21680 does not promote anergy or Treg induction during primary immunization.

Figure 1

B6 mice were immunized with 2W1S-PE and subsequently given a 7d treatment course of the selective A2aR agonist CGS 2.5 mg/kg or vehicle alone (PBS). (A) The frequency and number of spleen and LN 2W1S:I-Ab-specific CD4 T cells (with naïve untreated mice shown for reference). (B) Foxp3+ Tregs within the 2W1S:I-Ab-specific CD4 T cell compartment. (C) CD73+ FR4+ anergic-phenotype cells within the conventional Foxp3– 2W1S:I-Ab-specific CD4 T cell population. (D) Ki67 expression in conventional Foxp3– 2W1S:I-Ab-specific CD4 T cells 7d after 2W1S-PE immunization in the presence of CGS (2W1S peptide/CGS) or vehicle alone (2W1S peptide/PBS) (with endogenous naive polyclonal CD44lo CD4 T cells shown as a control). Data are representative from three independent experiments (n=8-9 mice per group). *P < 0.05, **P < 0.01, and ***P < 0.001